A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Inclusion Criteria:

• Has HCC confirmed histologically or cytologically, or, for patients with livercirrhosis, clinically by the American Association for the Study of Liver Diseases (AASLD) criteria

• Has had at least one line of systemic therapy for unresectable advanced ormetastatic disease

• Has at least one wingless-related integration site (WNT)-pathway activating mutation

• Child-Pugh class A or B7

Exclusion Criteria:

• Has fibrolamellar HCC, sarcomatoid HCC, or mixed cholangio-HCC tumors

• Has symptomatic extrahepatic disease

• Has received anti-cancer therapy or investigational drugs ≤3 weeks prior to thefirst dose of study drug

Note: other protocol defined inclusion / exclusion criteria apply